MAB672-100

antibody from R&D Systems

Targeting: CXCL11 b-R1, H174, I-TAC, IP-9, SCYB11, SCYB9B

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

MAB672-100

Provider

R&D Systems

Product name

Human CXCL11/I-TAC Antibody

Antibody type

Monoclonal

Description

Protein A or G purified from ascites. Detects human CXCL11/I-TAC in ELISAs and Western blots. In ELISAs, this antibody does not cross-react with recombinant human (rh) CXCL5, 7, 8, 9, or 10. In Western blots, this antibody shows less than 1% cross-reactivity with rhCXCL1, 2, 3, 5, 6, 7, IL-8/CXCL8, 9, 10, 13, CXCL12/SDF-1 alpha , CXCL12/SDF-1 beta , rmCXCL1, 2, 6, 9, 10, CXCL12/SDF-1 alpha , rmCXCL13, rrCXCL1, CXCL3/CINC-2 alpha , CXCL3/CINC-2 beta , or rpIL-8/CXCL8.

Reactivity

Human

Host

Mouse

Conjugate

Unconjugated

Antigen sequence

O14625


Isotype

IgG

Antibody clone number

87328

Vial size

100 ug

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation.

Pinto S, Martínez-Romero A, O'Connor JE, Gil-Benso R, San-Miguel T, Terrádez L, Monteagudo C, Callaghan RC
BMC cancer 2014 Feb 22;14:118

---

Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.

Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH
Journal of immunology (Baltimore, Md. : 1950) 2010 Mar 15;184(6):2886-98

---

Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.

Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY, Pflugfelder SC
Investigative ophthalmology & visual science 2010 Feb;51(2):643-50

---

Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients.

Winter D, Moser J, Kriehuber E, Wiesner C, Knobler R, Trautinger F, Bombosi P, Stingl G, Petzelbauer P, Rot A, Maurer D
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 15;179(6):4272-82

---

Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma.

Liu L, Jarjour NN, Busse WW, Kelly EA
American journal of respiratory and critical care medicine 2004 May 15;169(10):1118-24

---

Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands.

Kohrgruber N, Gröger M, Meraner P, Kriehuber E, Petzelbauer P, Brandt S, Stingl G, Rot A, Maurer D
Journal of immunology (Baltimore, Md. : 1950) 2004 Dec 1;173(11):6592-602

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Chemotaxis Induced by CXCL11/I-TAC and Neutralization by Human CXCL11/I-TAC Antibody. Recombinant Human CXCL11/I-TAC (Catalog # 672-IT) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL11/I-TAC (15 ng/mL) is neutralized (green line) by increasing concentrations of Human CXCL11/I-TAC Monoclonal Antibody (Catalog # MAB672). The ND₅₀ is typically 0.2-0.8 µg/mL.